Century Therapeutics, Inc.IPSC

Century Therapeutics (IPSC) reported a $21.6M net loss in Q1 2026, with negative operating cash flow of $25.3M, despite holding $134.8M in combined cash and short-term investments. The biotech, which claims to be building an ‘industry-leading’ allogeneic cell therapy platform, spent just $12k on R&D in the prior fiscal year, raising questions about its capital allocation as it advances candidates like CNTY-813 for type 1 diabetes and cancer.

Century’s official narrative centers on its iPSC-derived NK and T cell therapies, with presentations at the ADA 2026 Scientific Sessions highlighting preclinical data for CNTY-813. However, its SEC filings reveal a company reliant on dilution: 193.5M diluted shares outstanding and no buyback program to offset insider selling. Executives offloaded shares in mid-June at $15.20-$15.50, coinciding with the publication of its ADA presentation slides.

The company’s pipeline spans solid tumors and autoimmune diseases, but its financials show a cash burn rate that dwarfs its near-term revenue prospects. With $51M in cash and $83.8M in short-term investments, Century has runway-but its inability to generate positive cash flow from operations (-$25.3M in Q1) suggests a looming inflection point. The source directs readers to for updates on CNTY-813’s clinical timeline and any strategic partnerships to offset R&D costs.

Technical traders note IPSC’s stock has traded between $14.50 and $16.50 since June, with volume concentrated around its $15.30 average. The lack of significant price movement contrasts with the volatility typical of early-stage biotechs, possibly reflecting institutional holding patterns or event-driven stagnation ahead of potential catalysts.